|View printer-friendly version|
|LeMaitre Vascular Acquires ProCol® Vascular Bioprosthesis|
ProCol is a biological (bovine) graft indicated for vascular access subsequent to at least one failed prosthetic access graft. The ProCol device received PMA approval from the
In conjunction with the acquisition,
Guidance on how this acquisition may affect LeMaitre Vascular’s 2016 revenue and operating income expectations will be provided at the Company’s Q1 2016 earnings call on
LeMaitre and the
For more information about the Company, please visit http://www.lemaitre.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include, but are not limited to, the risk that the Company may not realize the anticipated benefits of its strategic activities and other risks and uncertainties included under the heading "Risk Factors" in its most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company's investor relations website at http://www.lemaitre.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
CONTACT: For information contact: